'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists

Thrombosis and Haemostasis

Volumn 111, Issue 3, 2013, Pages 539-548

  Glenn, Jacqueline R ^a   Dovlatova, Natalia ^a   White, Ann E ^a   Dhillon, Kiren ^a   Heptinstall, Stan ^a   Fox, Susan C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cyclic nucleotides; Cytometric bead assay; Platelets; VASP phosphorylation

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ILOPROST; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ARTICLE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INCUBATION TIME; NORMAL HUMAN; PERFORMANCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE FUNCTION;

CYCLIC NUCLEOTIDES; CYTOMETRIC BEAD ASSAY; P2Y12 ANTAGONISTS; PLATELETS; VASP PHOSPHORYLATION;

ADENOSINE; ADENOSINE DIPHOSPHATE; ALPROSTADIL; BIOMARKERS, PHARMACOLOGICAL; BLOOD PLATELETS; BUCLADESINE; CELL ADHESION MOLECULES; CELLS, CULTURED; CYCLIC AMP; HUMANS; ILOPROST; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PIPERAZINES; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THIOPHENES; THROMBOPHILIA; TICLOPIDINE;

EID: 84897088268     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-07-0581     Document Type: Article

References (30)

1. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153-1161.
2. Nolte C, Eigenthaler M, Schanzenbacher P et al. Comparison of vasodilatory prostaglandins with respect to cAMP-mediated phosphorylation of a target substrate in intact human platelets. Biochem Pharmacol 1991; 42: 253-262.
3. Geiger J, Brich J, Honig-Liedl P et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signalling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19: 2007-2011.
4. Sudo T, Ito H, Kimura Y. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. Platelets 2003; 14: 381-390.
5. Yamamoto H, Takahashi K, Watanabe H et al. Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation. Circ J 2008; 72: 1844-1851.
6. Yamanouchi J, Hato T, Niiya T et al. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol. Platelets 2010; 22: 135-142.
7. Aktas B, Utz A, Hoenig-Liedl P et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: In vitro and in vivo/ex vivo studies. Stroke 2003; 34: 764-769.
8. Chakrabarti S, Blair P, Wu C et al. Redox state of dipyridamole is a critical determinant for its beneficial antioxidant and antiinflammatory effects. J Cardiovasc Pharmacol 2007; 50: 449-457.
9. Schwarz UR, Geiger J, Walter U et al. 1999 Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-Definition and detection of ticlopidine/ clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
10. Barragan P, Bouvier J-L, Roquebert P-O et al. Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
11. Aleil B, Ravanat C, Cazenave JP et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92.
12. Blindt R, Stellbrink K, de Taeye A et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
13. Bonello L, Paganelli F, Arpin-Bornet M et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636.
14. Schäfer A, Weinberger S, Flierl U et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 2008; 100: 618-625.
15. Bouman HJ, Parlak E, van Werkum JW et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 8: 482-488.
16. Kleiman NS. Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel? J Am Coll Cardiol 2008; 51: 1412-1414.
17. Bonello L, Laine M, Baumstarck K et al. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. Int J Cardiol 2013; Epub ahead of print.
18. Barragan P, Paganelli F, Camoin-Jau L et al. Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. Thromb Haemost 2010; 104: 410-411.
19. Geiger J, Brandmann T, Hubertus K et al. A protein phosphorylation-based assay for screening and monitoring of drugs modulating cyclic nucleotide pathways. Anal Biochem 2010; 407: 261-269.
20. Jakubowski JA, Bourguet N, Boulay-Moine D et al. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition. Thromb Haemost 2012; 107: 388-395.
21. Abtan J, Silvain J, Kerneis M et al. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimu-lated phosphoprotein (VASP) phosphorylation assay. Thromb Haemost 2013; 110: 1055-1064.
22. Hobl EL, Jilma B, Derhaschnig U et al. Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y12-inhibition after ticagrelor intake. Cytometry B Clin Cytom 2013; Epub ahead of print.
23. Butt E, Abel K, Krieger M et al. cAMP-dependent and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in-vitro and in intact human platelets. J Biol Chem 1994; 269: 14509-14517.
24. Iyu D, Juttner M, Glenn JR et al. PGE(1) and PGE(2) modify platelet function through different prostanoid receptors. Prostagland Lipid Med 2011; 94: 9-16.
25. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2007; 357: 2001-2015.
26. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007; 5: 1545-1551.
27. Jaremo P, Lindahl TL, Fransson SG et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-238.
28. Judge HM, Buckland RJ, Sugidachi A et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217.
29. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117: 2102-2112.
30. Zighetti ML, Carpani G, Sinigaglia E et al. Usefulness of a flow cytometric analysis of intraplatelet vasodilator-stimulated phosphoprotein phosphorylation for the detection of patients with genetic defects of the platelet P2Y12 receptor for ADP. J Thromb Haemost 2010; 8: 2332-2334.